Recommendations for Improved Use of the Murine TNBS-Induced Colitis Model in Evaluating Anti-inflammatory Properties of Lactic Acid Bacteria: Technical and Microbiological Aspects
- 1 February 2006
- journal article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 51 (2), 390-400
- https://doi.org/10.1007/s10620-006-3143-x
Abstract
Probiotic bacteria have been shown to exert promising beneficial effects in different types of intestinal disorders, including chronic inflammation. In this context, animal models of inflammatory bowel disease are useful in studying the possible prophylactic role of candidate probiotic strains. This study aimed at evaluating the critical technological and microbiological parameters as well as the robustness of the murine trinitrobenzene sulfonic acid (TNBS)–induced model of colitis, after intragastric administration of lactic acid bacteria (LAB) preparations. A standardized methodology was applied to assess the protective effect achieved by various bacterial concentrations and culture conditions of the reference strain Lactobacillus plantarum NCIMB 8826. Not only was protection found to vary in function in different levels of colitis, but also repeated experiments showed a clear bacterial dose-dependent attenuation of colitis. The physiological stage of bacteria was shown to impact as well, with substantial, mild, or reduced improvement of inflammatory scores for exponentially growing, stationary-phase, or killed bacteria, respectively. A recombinant strain, secreting murine interleukin-10 (IL-10) and previously reported to successfully treat colitis in two different models of murine colitis (dextran sulfate sodium [DSS] and IL-10-deficient mice), was used to validate the final experimental conditions. In conclusion, we identified and optimized some of the key parameters that need to be controlled in order to ensure reliable comparison of results generated over a long period of time or independent experiments. The recommendations for an improved model presented here will prove to be helpful for reproducible, independent comparison of the anti-inflammatory potential of wild-type or recombinant candidate probiotic strains, whether administered as pure cultures or as blends.Keywords
This publication has 52 references indexed in Scilit:
- Beneficial effect of auto-aggregatingLactobacillus crispatuson experimentally induced colitis in miceFEMS Immunology & Medical Microbiology, 2005
- Use of Mouse Models To Evaluate the Persistence, Safety, and Immune Modulation Capacities of Lactic Acid BacteriaClinical and Vaccine Immunology, 2003
- IL-10 gene therapy prevents TNBS-induced colitisGene Therapy, 2002
- Probiotics and inflammatory bowel disease: from fads and fantasy to facts and futureBritish Journal of Nutrition, 2002
- The Immunology of Mucosal Models of InflammationAnnual Review of Immunology, 2002
- Influence of Interleukin-10 on the Interleukin-1 Receptor Antagonist/Interleukin-1β Ratio in the Colonic Mucosa of Ulcerative ColitisDigestion, 2001
- Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tractAlimentary Pharmacology & Therapeutics, 2000
- Probiotic Therapy Fails to Improve Gut Permeability in a Hapten Model of ColitisScandinavian Journal of Gastroenterology, 2000
- Antibodies to interleukin 12 abrogate established experimental colitis in mice.The Journal of Experimental Medicine, 1995
- Colonic bacteria and bacterial translocation in experimental colitisBritish Journal of Surgery, 1993